Just a matter of time for a huge breakout to $1++
Institutions will be all over this puppy
I agree 100%
MSTX is ridiculously underpriced considering that it has 40c/share cash and no debt ....and now with two multi-billion dollar assets
Tax selling over tomorrow
January Effect to start in earnest on Monday
and I believe the market close at 12 tomorrow ??
I agree...I see 15c ++ next week
Was lucky to get 10K at $1.31
Low floater FORD will be a $5 stock in 2016 as January effect nears and profitable 1Q will be reported in only 6 weeks.
2016 will be massively superior to 2015
Just a few more days for delisting notice
Reactive molecules such as chemotherapy agents (including the standard of care for SCD), kill healthy tissue, and the reaction products can be even more damaging to the body than the original molecules.
unlike chemotherapy or most molecules being used to treat severe diseases, Poloxamer is inert and it's main purpose is to improve blood flow, protect red blood cells and platelets thus minimizing tissue damage (most importantly the heart) and improving overall body functioning.
Poloxamer's applicability is limitless. I see Vepo being used to prevent SCD episodes instead of just helping in crisis situations....to prevent heart attacks....to protect red blood cells and platelets during chemotherapy, etc.
My 12 month target is $8
Thank you for the timely tip.
Last year FORD reported on 12/9...
See FORD's chart and judge for yourself..
This quarter will be the second profitable quarter in a row and it will beat last years's numbers by a mile.
I see a double here
MSTX with 35c/share cash and no debt will present at two key conferences next week (check out company news on Yahoo and get in before it takes off). Here is what Maxim said last week:
Mast's vepoloxamer is now in a pivotal phase III (EPIC) study. Data for the treatment of pain crises in sickle cell disease (SCD) is expected by 1Q16. If positive and pending approval, vepoloxamer could be on the market by 2017 in the U.S. and 2018 in Europe.
How big is the opportunity? Vepoloxamer would be the second drug approved for sickle cell disease — and the only drug approved for treating crises directly. Sweetening the opportunity is the fact that the 100,000 annual sickle cell hospitalizations in the U.S. for pain crises take place in fewer than 200 hospitals, meaning the launch trajectory could be steep.
Mast is a value play for investors, in our opinion. What we believe to be due to a prior phase III failure, Mast’s valuation is distressed. However, lessons learned have helped Mast design the ongoing EPIC study to be better powered and to have the right endpoint and the right patients. Thus, the probability of success has been optimized, in our view. Additionally, the excitement of gene therapy in SCD is overshadowing what appears to be a critical and important new viable therapeutic option for patients.
Mast is a phase 3 company, with a sub $100M market cap and $45M in cash with data expected in 1Q16. Given the design of the EPIC study (built on the shoulders of the prior study) of vepoloxamer we believe the probability of success is high. Mast could have the first SCD drug to treat pain crises.
AEZS has two drugs in Phase 3 clinical trials (one cancer) and three drugs in Phase 2 with one just recently having successfully met Phase 2 prostate cancer endpoints.
Mean Recommendation (this week): 1.7
Mean Recommendation (last week): 1.7
* (Strong Buy) 1.0 - 5.0 (Sell)
Price Target Summary
Mean Target: 65.33
Median Target: 11.00
High Target: 175.00
Low Target: 10.00
No. of Brokers: 3
Load up at these rock-bottom prices.......because institutions will. The float is only 5M shares now
$4.8 last trade up 15%
I approve this message